Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Sunday, November 17, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Sunday, November 17, 2024 | Latest Paper
Subscribe Now

TRENDING:

Michael May

Michael May, PhD, is president and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. 

Canada’s biomedical brain drain is reversing. Let’s continue that trend

  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.
Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute

Canada’s biomedical brain drain is reversing. Let’s continue that trend

Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.

Canada’s biomedical brain drain is reversing. Let’s continue that trend

Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute

Canada’s biomedical brain drain is reversing. Let’s continue that trend

  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.
Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute

Canada’s biomedical brain drain is reversing. Let’s continue that trend

Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.

Canada’s biomedical brain drain is reversing. Let’s continue that trend

Opinion | BY MICHAEL MAY, ALLISON BROWN | January 8, 2024
  • We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.
To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute

Time to go on offence with Canada’s bio-manufacturing strategy

  • The COVID-19 pandemic is a health-care crisis. It has, in many ways, focused a lens on the importance of the life sciences, technology development,
Opinion | BY MICHAEL MAY | September 13, 2021
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless

Time to go on offence with Canada’s bio-manufacturing strategy

Opinion | BY MICHAEL MAY | September 13, 2021
  • The COVID-19 pandemic is a health-care crisis. It has, in many ways, focused a lens on the importance of the life sciences, technology development,

Time to go on offence with Canada’s bio-manufacturing strategy

Opinion | BY MICHAEL MAY | September 13, 2021
  • The COVID-19 pandemic is a health-care crisis. It has, in many ways, focused a lens on the importance of the life sciences, technology development,
Stainless steel bioreactors, pictured. It is encouraging and exciting that bio-manufacturing has become a priority of the Canadian life sciences enterprise, and it is understandable that recent investments have been driven by COVID-19 vaccine development and manufacturing, writes Michael May. Photograph courtesy of Commons Wikimedia/Rick Lawless
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Advertise

get help

Subscribe
CloseMenu